Fig. 6: Humoral responses post-challenge. | npj Vaccines

Fig. 6: Humoral responses post-challenge.

From: Inactivated rabies-based Lassa fever virus vaccine candidate LASSARAB protects nonhuman primates from lethal disease

Fig. 6

a Antibody responses against LASV-GPC pc. Total IgG EC50 antibody titers throughout the course of the challenge study. Error bars indicate standard deviation. Statistics at each timepoint were determined by the Mann–Whitney non-parametric T-test. Where significance is not noted, samples have no significant difference. ****<0.0001; ***0.0002; **0.0021; *0.0332; P > 0.05 ns, not significant. b The serum neutralization levels were measured in a microneutralization assay using three-fold serial dilutions starting at 1:10. The bar graph shows LASV Neut50 endpoint titer (EPT), defined as the highest serum dilution achieving a neutralization of at least 50 percent of the control LASV virus. The error bars represent the standard deviation, with the x-axis representing the sampling timepoint and y-axis, the reciprocal serum dilutions. c Percent inhibition curves were plotted in GraphPad Prism 9.4.0 with reciprocal serum dilution on the x-axis and percent inhibition on the y-axis. The individual data points shown for each cynomolgus macaque represent the mean ± standard deviation among two replicates on days 10, 14, 21, and 28 pc.

Back to article page